The Hong Kong Investment Corporation Limited (“HKIC”) is wholly owned by the Government of the Hong Kong Special Administrative Region (“HKSARG”). As Patient Capital, we carry a dual mandate - seeking reasonable financial return over the medium to long term, and more importantly, enhancing the long-term competitiveness and economic vitality of Hong Kong. We play an important role in curating synergy among the HKSARG, industry, academia, research and investment sectors.
Size of our initial capital for deployment is HK$62 billion, covering the “Hong Kong Growth Portfolio”, “Greater Bay Area Investment Fund”, “Strategic Tech Fund”, and “Co-Investment Fund”. Currently, our key investment themes are Hard & Core Technology, Biotechnology, and New Energy & Green Technology, and the relevant applications.
Currently, our key investment themes are Hard & Core Technology, Biotechnology, and New Energy & Green Technology, and the relevant applications. We will add more as we continue our journey to invest for the future of Hong Kong.
We play an important role in curating synergy among the HKSARG, industry, academia, research and investment sectors. We require our strategic partners and portfolio companies to support the future development of Hong Kong. We prioritise “platform” projects which success will also benefit the development of other partners and companies in the HKIC ecosystem.
Our partners and projects cover those originated and based in Hong Kong, and also those that go beyond Hong Kong. All of them have to fit our dual mandate.
Hong Kong Investment Corporation Limited issues invitation for proposals regarding fund managers of the Investment Portfolio under the New Capital Investment Entrant Scheme (November 2024)
More details